Docoh
Loading...

GTHX G1 Therapeutics

APP
Utility
Transient Protection of Normal Cells During Chemotherapy
30 Sep 21
This invention is in the area of improved compounds, compositions and methods of transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC) as well as renal cells, from damage associated with DNA damaging chemotherapeutic agents.
Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis Xavier Tavares
Filed: 5 Apr 21
APP
Utility
Therapeutic Regimens for Treatment of Cancer Using Eribulin and Selective CDK4/6 Inhibitor Combinations
2 Sep 21
The present invention provides methods and compositions for treating cancers with a combination of eribulin and a selective CDK4/6 inhibitor, wherein the selective CDK4/6 inhibitor reduces eribulin's effects on myelosuppression and/or myeloablation without reducing the efficacy of eribulin therapy.
Jessica A. Sorrentino, Patrick Joseph Roberts, Jay Copeland Strum
Filed: 7 May 21
GRANT
Utility
Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
17 Aug 21
This invention is in the area of improved therapeutic combinations for and methods of treating selected retinoblastoma (Rb)-negative cancers and Rb-negative abnormal cellular proliferative disorders using particular topoisomerase inhibitors and specific cyclin-dependent kinase 4/6 (CDK4/6) inhibitors.
Jay Copeland Strum, John E. Bisi, Patrick Joseph Roberts, Jessica A. Sorrentino
Filed: 16 Sep 19
APP
Utility
Hspc-sparing Treatments for Rb-positive Abnormal Cellular Proliferation
15 Jul 21
This invention is in the area of improved compounds for and methods of treating selected RB-positive cancers and other Rb-positive abnormal cellular proliferative disorders while minimizing the deleterious effects on healthy cells, for example healthy Hematopoietic Stem Cells and Progenitor Cells (HSPCs), associated with current treatment modalities.
Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis X. Tavares
Filed: 22 Feb 21
GRANT
Utility
Transient protection of normal cells during chemotherapy
22 Jun 21
This invention is in the area of improved compounds, compositions and methods of transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC) as well as renal cells, from damage associated with DNA damaging chemotherapeutic agents.
Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis Xavier Tavares
Filed: 28 May 20
APP
Utility
Synthesis of 1,4-DIAZASPIRO[5.5]UNDECAN-3-ONE
17 Jun 21
This invention provides a process for preparing 1,4-diazaspiro[5.5]undecan-3-one and analogues thereof that are useful in the preparation of pharmaceutical compound, including for the treatment of disorders involving abnormal cellular proliferation.
Stephen E. Schneider, Hannah White, Thomas Fessard, Sagar Beldar
Filed: 24 Feb 21
APP
Utility
Benzothiophene Estrogen Receptor Modulators to Treat Medical Disorders
10 Jun 21
This invention is a benzothiophene estrogen receptor modulator or its pharmaceutically acceptable salt, N-oxide, isotopic derivative, or prodrug thereof or a pharmaceutically acceptable composition thereof to treat an estrogen-related medical disorder.
Jay Copeland Strum
Filed: 16 Feb 21
APP
Utility
Synthesis of N-(HETEROARYL)-PYRROLO[3,2-D]PYRIMIDIN-2-AMINES
29 Apr 21
This invention is in the area of synthesizing pyrimidine-based compounds useful in the treatment of disorders involving abnormal cellular proliferation, including but not limited to tumors and cancers.
Alexander Smith, Hannah S. White, Francis Xavier Tavares, Sergiy Krasutsky, Jian-Xie Chen, Roberta L. Dorrow, Hua Zhong
Filed: 14 Dec 20
GRANT
Utility
Morphic forms of trilaciclib and methods of manufacture thereof
27 Apr 21
An advantageous isolated morphic form of trilaciclib which is 2′-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7′,8′-dihydro-6′H-spiro[cyclohexane-1,9′-pyrazino[1′,2′:1,5]pyrrolo[2,3-d]pyrimidin]-6′-one, for example in the form of a di-hydrochloride salt or a dihydrochloride, dihydrate.
Stephen Schneider, Alexander Smith, Hannah S. White, Jay Copeland Strum, Jaroslaw Mazurek
Filed: 13 Nov 20
GRANT
Utility
Transient protection of normal cells during chemotherapy
6 Apr 21
This invention is in the area of improved compounds, compositions and methods of transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC) as well as renal cells, from damage associated with DNA damaging chemotherapeutic agents.
Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis Xavier Tavares
Filed: 24 Aug 18
APP
Utility
Transient Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation
18 Mar 21
This invention is in the area of improved compounds and methods for transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC), from the damage associated with ionizing radiation (IR) exposure using selective radioprotectants.
Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis Xavier Tavares
Filed: 23 Nov 20
GRANT
Utility
HSPC-sparing treatments for RB-positive abnormal cellular proliferation
23 Feb 21
Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis Xavier Tavares
Filed: 1 Nov 18
GRANT
Utility
CDK inhibitors
23 Feb 21
Compounds of Formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
Francis X. Tavares, Jay Copeland Strum
Filed: 13 May 20
APP
Utility
Pyrimidine-based Antiproliferative Agents
18 Feb 21
This invention is in the area of pyrimidine-based compounds for the treatment of disorders involving abnormal cellular proliferation, including but not limited to tumors and cancers.
Jay Copeland Strum, David Jung
Filed: 3 Nov 20
APP
Utility
Treatment of Cancers Having Driving Oncogenic Mutations
4 Feb 21
Methods and compositions are described to treat a cancer having a specific oncogenic driving mutation by administering a CDK4/6 inhibitor in combination with an additional kinase inhibitor, wherein the specific combination provides advantageous or synergistic inhibitory activity, delays acquired resistance to the additional kinase inhibitor, and/or extends the efficacy of the kinase inhibitor.
Jay Copeland Strum, Daniel M. Freed, Jessica A. Sorrentino, John E. Bisi, Andrew Beelen, Patrick Joseph Roberts
Filed: 9 Oct 20
APP
Utility
G1T38 Superior Dosage Regimes
30 Dec 20
A G1T38 human oral dosage regime that provides a (mean AUC(0-24),ss (h*ng/mL))/(dose (mg)) ratio of less than 5 and/or a (mean AUC(0-24),ss (h*ng/mL))/(Absolute Neutrophil Count (cells/mm3)) ratio on day 22 of dosing of not greater than 1.25.
Andrew Beelen, Jay Copeland Strum
Filed: 7 Jul 20
GRANT
Utility
Synthesis of n-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-amines
14 Dec 20
This invention is in the area of synthesizing pyrimidine-based compounds useful in the treatment of disorders involving abnormal cellular proliferation, including but not limited to tumors and cancers.
Alexander Smith, Hannah S. White, Francis Xavier Tavares, Sergiy Krasutsky, Jian-Xie Chen, Roberta L. Dorrow, Hua Zhong
Filed: 20 Dec 18
GRANT
Utility
Substituted dihydropyrazino[1 ′,2′:1,5]pyrrolo[2,3-d]pyrimidine-based antiproliferative agents
9 Nov 20
Jay Copeland Strum, David Jung
Filed: 20 Dec 18
APP
Utility
Transient Protection of Normal Cells During Chemotherapy
4 Nov 20
This invention is in the area of improved compounds, compositions and methods of transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC) as well as renal cells, from damage associated with DNA damaging chemotherapeutic agents.
Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis Xavier Tavares
Filed: 27 May 20
APP
Utility
Highly Active Anti-neoplastic and Anti-proliferative Agents
4 Nov 20
This invention is in the area of improved compounds and methods for treating selected cancers and hyperproliferative disorders.
Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis Xavier Tavares
Filed: 9 Jul 20
Patents are sorted by USPTO publication date, most recent first